


Fuchs CS et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. Proc ASCO 2011;Abstract 4003.


Phillips BE et al. Clinicopathologic features and treatment outcomes of patients (pts) with HER2-positive (pos) adenocarcinomas (ACA) of the esophagus (E) and gastroesophageal junction (GEJ). Proc ASCO 2011;Abstract 4046.


Clinical practice surveillance of the use of Herceptin in patients with HER2-positive advanced adenocarcinoma of the stomach or gastro-esophageal junction (GEJ) (HERMES). NCT01220934.

Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction, metastatic or not amenable to curative surgery according to HER2 and EGFR status: A randomized Phase II trial. NCT01123473.

Lapatinib versus lapatinib with capecitabine as second-line treatment in HER2-overexpressing metastatic gastro-esophageal cancer: A randomized Phase II trial. NCT01145404.

Phase II trial of CAPOX, bevacizumab and trastuzumab for patients with HER2-positive metastatic esophagogastric cancer. NCT01191697.

Radiation therapy, paclitaxel, and carboplatin with or without trastuzumab in treating patients with esophageal cancer. NCT01196390.

REAL 3 version 2.0: Trial of the efficacy of epirubicin, oxaliplatin and capecitabine (EOX) with or without panitumumab in previously untreated advanced oesophago-gastric cancer. NCT00824785.

Safety and efficacy of RAD001 (everolimus) monotherapy plus best supportive care in patients with advanced gastric cancer (AGC) (GRANITE-1). NCT00879333.